摘要
目的 探讨胃癌患者中EGFR、HER2、VEGF的表达水平与术后行SOX化疗方案疗效的相关性.方法 选取2017年至2019年胃癌患者142例,检测患者胃癌组织中EGFR、HER2、VEGF的表达水平,绘制其SOX化疗方案后的生存曲线.结果 142例患者中EGFR、HER-2、VEGF阳性表达分别为34例(24％)、44例(31％)和100例(70％).单因素分析显示EGFR的阳性表达与分化程度、Lauren分型、术前CA19-9及术前CEA水平有关;HER-2的阳性表达与性别、临床分期、Lauren分型有关;VEGF的阳性表达与年龄、血管侵犯有关.多因素分析显示Lauren分型弥漫型及术前较高CA19-9及CEA水平是EGFR高表达的独立危险因素;男性及Ⅲ+Ⅳ期及Lauren分型弥漫型是HER-2高表达的独立危险因素;血管侵犯会增加VEGF的表达.结论 胃癌组织中EGFR、HER-2的高表达与SOX化疗方案的疗效有关.
Abstract
Objective To identify the association between the expression of EGFR,HER2 and VEGF in patients with gastric cancer and the efficacy of SOX regimen performed after surgery.Methods Select 142 gastric cancer patients from 2017 to 2019,measure the expression levels of EGFR,HER2,and VEGF in their gastric cancer tissues,and plot their survival curves after SOX chemotherapy regimen.Results Among the 142 patients,EGFR,HER2,and VEGF were positively expressed in 34 cases(24％),44 cases(31％),and 100 cases(70％),respectively.Univariate analysis showed that the positive expression of EGFR was related to differentiation degree,Lauren classification,preoperative CA19-9 and CEA levels.The positive expression of HER2 was related to gender,clinical stage,and Lauren classification.The positive expression of VEGF was related to age and vascular invasion.Multivariate analysis showed that Lauren's diffuse type and preoperative high levels of CA19-9 and CEA were independent risk factors for EGFR overexpression.Male and stage Ⅲ+Ⅳ,as well as Lauren's diffuse subtype,were independent risk factors for HER2 overexpression.Vascular invasion could increase the expression of VEGF.Conclusion The high expression of EGFR and HER2 in gastric cancer tissue is associated with the efficacy of SOX chemotherapy regimen.
维普
万方数据